Trials / Completed
CompletedNCT03403790
A Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
Drug Use-results Survey on Quetiapine Extended-release Tablets in Patients With Depression in Bipolar Disorder
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 369 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety and effectiveness of quetiapine in actual clinical settings.
Detailed description
This is a post-marketing use-result survey study required for products in Japan. The investigator will register the patient who have been taking this product for the first time within 14 days after the start of treatment (inclusive of the start day). For each of the registered patients (including withdrawals and dropouts), the investigator will enter the survey data on the case report form.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Quetiapine | Oral (extended-release tablet) |
Timeline
- Start date
- 2018-01-15
- Primary completion
- 2020-03-19
- Completion
- 2020-03-19
- First posted
- 2018-01-19
- Last updated
- 2024-10-16
Locations
47 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT03403790. Inclusion in this directory is not an endorsement.